Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: fracture

Tanezumab for OA Pain

Michele B. Kaufman, PharmD, BCGP  |  February 21, 2019

In a recent study, tanezumab proved more effective than placebo in treating patients with moderate to severe pain caused by hip or knee osteoarthritis…

Filed under:AnalgesicsDrug Updates

WindNight / shutterstock.com

Why & How Our Biologic Drug Discussion with Patients Should Evolve

Paul H. Caldron, DO, PhD, MBA, & John R.P. Tesser, MD  |  February 17, 2019

As we turn the corner on the second decade of biologic use for rheumatic disorders, a reappraisal of approach in our communication with patients is due. In practice, the impact these agents have on patients’ lives justifies the friction rheumatologists face when connecting patients to them. You can understand why older rheumatologists who apprenticed on…

Filed under:Biologics/DMARDsResearch RheumRheumatoid ArthritisSpeak Out Rheum Tagged with:OpinionSpeak Out Rheumatology

FDA Advisory Committee Votes in Favor of Romosozumab Approval

Michele B. Kaufman, PharmD, BCGP  |  January 30, 2019

An FDA advisory committee voted 18-1 in favor of approving romosozumab to treat postmenopausal women with osteoporosis.

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:boneFDAOsteoporosisromosozumabU.S. Food and Drug Administration (FDA)

Do Osteoporosis Screening Guidelines Meet Patient Needs?

Lara C. Pullen, PhD  |  January 21, 2019

A recent study found that clinical practice guidelines for osteoporosis screening vary in quality and recommendations—even within the same country. Assessing guidelines from 13 countries, researchers found osteoporosis screening standards have not improved over time and many fail to include patients in guideline development…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:GuidelinesOsteoporosisscreening

Do Not Get Us Started on Acthar

Do Not Get Us Started on Acthar

Megan Elizabeth Bowles Clowse, MD, MPH & David Leverenz, MD  |  December 17, 2018

As rheumatologists, we have a love-hate relationship with the corticosteroid prednisone, a feeling many of our patients share. It’s our most effective medication to quickly shut down an overactive immune system. When we have a patient with life- or organ-threatening autoimmune disease—severe lupus affecting the kidneys or vasculitis causing hemorrhage in the lungs, for example—large…

Filed under:OpinionSpeak Out Rheum Tagged with:Actharadrenocorticotropic hormoneCorticosteroidsDrug UpdatesOpinionprednisone

Post-Traumatic Osteoarthritis: Managing OA That Develops After Joint Injuries & Reconstructive Surgery

Susan Bernstein  |  November 28, 2018

CHICAGO—Joint trauma is one of many potential drivers of osteoarthritis disease activity and structural progression. In Post-Traumatic OA: Pathogenesis, Clinical Evolution and Management, a session at the 2018 ACR/ARHP Annual Meeting, experts discussed the effects of sports and other injuries on even young patients’ joints. Post-traumatic osteoarthritis (OA) may account for 12% of hip, knee…

Filed under:American College of RheumatologyConditionsMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:2018 ACR/ARHP Annual Meeting

Coding Corner Questions: A Drug Administration Quiz

From the College  |  November 19, 2018

A 70–year-old female patient with rheumatoid arthritis affecting multiple joints who is rheumatoid-factor positive but without organ or system failure returns for her third infliximab infusion. She is scheduled to receive 500 mg of the drug. How should this encounter be coded? 96413, 96415, J1745 x 50; ICD 10: M05.79 96413, 96415, J1745 x 50;…

Filed under:Billing/CodingFrom the College Tagged with:adalimumabBilling & Codingdenosumabibandronate sodiuminfliximab

Case Report: Acne Drug Leads Patient to Retinoid Hyperostosis

Rachael Stovall, MD, Akira M. Murakami, MD, & Maureen Dubreuil, MD, MSc  |  November 19, 2018

Presentation A 26-year-old man with a history of acne vulgaris and hidradenitis suppurativa presented to our rheumatology clinic with persistent back pain and stiffness of three years’ duration. He described bilateral low back pain that was worse when he arose in the morning and at night when he was trying to sleep. In a similar…

Filed under:Axial SpondyloarthritisConditions Tagged with:Ankylosing SpondylitisisotretinoinRetinoid Hyperostosis

New Joint Space Mapping Technique Doubles Diagnostic Sensitivity for Osteoarthritis

Renée Bacher  |  November 18, 2018

Traditional X-rays, move over—there may be a new gold standard for joint imaging to assess even the smallest changes that can signal the onset of arthritis, as reported recently in the journal Scientific Reports.1 Utilizing the combined expertise of radiologists, rheumatologists and engineers, University of Cambridge researchers developed an algorithm to monitor the joints of…

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:OsteoarthritisTesting

A Balancing Act: Tips to Ensure Optimal Screening & Treatment for Osteoporosis

Carina Stanton  |  November 12, 2018

Patients with rheumatic diseases may be undertreated for osteoporosis. To decrease fracture risk for at-risk patients, rheumatologists can engage patients in shared decision making with regular screening and education about treatment options…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bonefracture riskFracturesOsteoporosispatient care

  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 43
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences